AI filing briefs · archive

8-K filings in November 2024, explained

513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

2 of 513 briefs match

newest first · times in ET

QNSTQUINSTREET, INC Nov 4, 4:15 PM ET

QuinStreet revenue rises 125% to $279 million and full-year fiscal 2025 outlook is raised

Positive guidance Written later 2.02

QuinStreet reported fiscal first-quarter revenue of $279.2 million, up 125% from a year earlier, and a GAAP net loss of $1.4 million, or $(0.02) per diluted share, compared with a $10.6 million loss a year earlier. The company raised its full fiscal 2025 revenue and adjusted EBITDA outlook, though it said it is still early in the year.

Revenue of $279.2 million, up 125% year over year; Financial Services revenue was $210.9 million and Home Services revenue was $65.1 million
GAAP net loss of $1.4 million, or $(0.02) per diluted share, versus a net loss of $10.6 million a year earlier; adjusted EBITDA was $20.3 million versus $984 thousand
Fiscal second-quarter outlook: revenue of $235 million to $245 million and adjusted EBITDA of $17.5 million to $18.5 million
Full fiscal 2025 outlook raised: revenue of $975 million to $1.025 billion and adjusted EBITDA of $75 million to $80 million

Read the filing on SEC.gov ↗

TGTXTG THERAPEUTICS, INC. Nov 4, 7:19 AM ET

TG Therapeutics raises 2024 BRIUMVI revenue guidance to $300 million-$305 million

Mixed guidance Written later 2.02

TG Therapeutics reported third quarter 2024 results and raised its full-year 2024 U.S. BRIUMVI net product revenue target to $300 million to $305 million, up from $290 million to $300 million. Product sales are growing quickly, but total revenue and net income fell sharply from the prior-year period, which included a large license payment.

Q3 2024 U.S. BRIUMVI net product revenue was $83.3 million, about 15% above the prior quarter and over 230% above Q3 2023.
Full-year 2024 U.S. BRIUMVI net revenue target raised to $300 million to $305 million from $290 million to $300 million.
Q3 2024 net income was $3.9 million, compared with $113.9 million in Q3 2023, which included license revenue of $140.7 million.
Cash, cash equivalents and investment securities were $341.0 million as of September 30, 2024.

Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.